<DOC>
	<DOCNO>NCT01259063</DOCNO>
	<brief_summary>The purpose study test safety gemcitabine apply bladder directly combine different oral dos everolimus assess right dos . Gemcitabine give fix dose . Up 3 dose level everolimus evaluate . The purpose phase II part test combination gemcitabine apply bladder directly combine different oral dos everolimus study effect two drug together . The investigator want find effect , good and/or bad , treatment patient cancer .</brief_summary>
	<brief_title>RAD001 Intravesical Gemcitabine BCG-Refractory Primary Secondary Carcinoma In Situ Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients must Bacille CalmetteGuérin ( BCG ) refractory primary secondary TisN0M0 BCGrefractory disease define : Patient positive Cis 2 consecutive BCG installation OR , patient BCG response failure within 6 month OR , patient Cis maintenance BCG OR , patient persistent Cis 6 month least one instillation BCG OR , patient BCG intolerant OR , criteria patient history T1 disease OR , patient BCGrelapsing disease , define failure 6 month patient diseasefree Pathologic confirmation urothelial carcinoma enrol institution Karnofsky Performance Status ( KPS ) ≥ 70 % Age ≥ 18 year Adequate bone marrow function show : ANC ≥ 1.5 x 109/L , Platelets ≥ 100 x 109/L , Hb &gt; 9 g/dL Adequate liver function show : serum bilirubin ≤ 1.5 x ULN ( upper limit normal ) ALT AST ≤ 2.5x ULN International normalize ratio ( INR ) ≤1.5 x ULN ( Anticoagulation allow target INR ≤ 1.5 x ULN stable dose warfarin stable dose low molecular weight ( LMW ) heparin &gt; 2 week Adequate renal function : serum creatinine ≤ 1.5 x ULN Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fast triglyceride ≤ 2.5 x ULN . NOTE : In case one threshold exceed , patient include initiation appropriate lipidlowering medication . After lipidlowering therapy , patient must meet criterion , i.e . fast serum cholesterol &lt; 300 mg/dL OR &lt; 7.75 mmol/L AND fast triglyceride &lt; 2.5 x ULN , eligible study treatment . Pretreatment tumor tissue ( minimum 10 slide ) 1 paraffinembedded block available analysis mTOR pathway marker . Testing hepatitis B viral load serological marker ( Hepatitis B PCR quantitative , HBsAg , HBsAb , HBcAb ) follow patient : All patient currently live ( live ) Asia , Africa , Central South America , Eastern Europe , Spain , Portugal , Greece Patients follow risk factor : Known suspect past hepatitis B infection Blood transfusion ( ) prior 1990 Current prior IV drug user Current prior dialysis Household contact hepatitis B infect person ( ) Current prior highrisk sexual activity Body pierce tattoos Mother know hepatitis B History suggestive hepatitis B infection , e.g . dark urine , jaundice , right upper quadrant pain Additional patient discretion site Principal Investigator Testing hepatitis C infection ( use quantitative RNAPCR ) patient follow risk factor : Known suspect past hepatitis C infection ( include patient past interferon `` curative '' treatment ) Blood transfusion ( ) prior 1990 Current prior IV drug user Household contact hepatitis C infect person ( ) Current prior highrisk sexual activity Body pierce tattoos Additional patient discretion site Principal Investigator Patients currently receive anticancer therapy receive anticancer therapy within 4 week start study drug ( include chemotherapy , radiation therapy , antibody base therapy , etc . ) exception topical antineoplastic agent use treat malignancy Patients , major surgery significant traumatic injury within 4 week start study drug , patient recover side effect major surgery patient may require major surgery course study . Prior treatment investigational drug within precede 4 week Patients receive chronic , systemic treatment corticosteroid another immunosuppressive agent . Topical inhale corticosteroid allow . Patients receive immunization attenuate live vaccine within 1 week study entry study period Other malignancy within past 3 year , except adequately treat carcinoma cervix , basal squamous cell carcinoma skin adenocarcinoma prostate treat . Patients severe and/or uncontrolled medical condition condition could affect participation study : symptomatic congestive heart failure New York Heart Association Class III IV unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction within 6 month start study drug , serious uncontrolled cardiac arrhythmia , clinically significant cardiac disease Severely impaired lung function define spirometry diffuse capacity lung carbon monoxide ( DLCO ) 50 % normal predict value and/or 02 saturation 88 % less rest room air uncontrolled diabetes define fast serum glucose &gt; 1.5 x ULN active ( acute chronic ) uncontrolled severe infection include urinary tract infection liver disease cirrhosis , chronic active hepatitis , chronic persistent hepatitis A known history HIV seropositivity Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption Everolimus ( eg , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , smallbowel resection ) Patients active , bleed diathesis Female patient pregnant breast feeding , Women childbearing potential ( WOCBP ) must negative serum pregnancy test within 7 day prior administration Everolimus . Women childbearing potential ( WOCBP ) , define woman physiologically capable become pregnant , unless use highly effective method contraception dose study treatment . High effective contraception method include combination two follow ( a+b a+c b+c ) : Use oral , injected implant hormonal method contraception ; Placement intrauterine device ( IUD ) intrauterine system ( IUS ) ; Barrier method contraception : condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository ; Total abstinence ; Male/female sterilization . Women consider postmenopausal childbearing potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week prior registration . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . Male patient whose sexual partner ( ) WOCBP willing use adequate contraception study 8 week end treatment . Patients know hypersensitivity Everolimus rapamycins ( sirolimus , temsirolimus ) excipients History noncompliance medical regimen Patients unwilling unable comply protocol Prior radiation pelvis bladder cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>GEMCITABINE</keyword>
	<keyword>RAD001 ( EVEROLIMUS )</keyword>
	<keyword>urinary</keyword>
	<keyword>BCG-Refractory</keyword>
	<keyword>Intravesical</keyword>
	<keyword>10-165</keyword>
</DOC>